According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
Several other brokerages have also issued reports on ANAB. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the company a buy rating in a report on Monday, June 24th. Credit Suisse Group cut their price objective on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a neutral rating on the stock in a report on Friday, June 21st. Stifel Nicolaus lowered shares of AnaptysBio from a buy rating to a hold rating and cut their price objective for the company from $124.00 to $74.00 in a report on Friday, June 21st. Cantor Fitzgerald lifted their price objective on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a buy rating in a report on Tuesday, April 2nd. Finally, SunTrust Banks reissued a buy rating and set a $35.00 price objective on shares of Whiting Petroleum in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $111.25.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. Equities research analysts forecast that AnaptysBio will post -3.76 EPS for the current fiscal year.
In other news, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the sale, the insider now directly owns 32,437 shares in the company, valued at $2,369,847.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction on Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the sale, the chief executive officer now owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The disclosure for this sale can be found here. 14.00% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the company. Tekla Capital Management LLC increased its holdings in AnaptysBio by 43.4% in the fourth quarter. Tekla Capital Management LLC now owns 65,845 shares of the biotechnology company’s stock valued at $4,200,000 after buying an additional 19,935 shares in the last quarter. FMR LLC increased its holdings in AnaptysBio by 2.0% in the fourth quarter. FMR LLC now owns 4,012,735 shares of the biotechnology company’s stock valued at $255,973,000 after buying an additional 77,268 shares in the last quarter. TD Asset Management Inc. increased its holdings in AnaptysBio by 45.4% in the first quarter. TD Asset Management Inc. now owns 20,509 shares of the biotechnology company’s stock valued at $1,498,000 after buying an additional 6,400 shares in the last quarter. Millennium Management LLC increased its stake in shares of AnaptysBio by 11,829.2% during the fourth quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock worth $16,498,000 after purchasing an additional 256,456 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of AnaptysBio by 94.6% during the fourth quarter. Deutsche Bank AG now owns 74,864 shares of the biotechnology company’s stock worth $4,774,000 after purchasing an additional 36,395 shares in the last quarter.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.